503170674 02/09/2015

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT3217289

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
ACTION MEDICINES, S.L.	11/15/2011

RECEIVING PARTY DATA

Name:	AMDERMA PHARMACEUTICALS, LLC
Street Address:	400 CROSSING BOULEVARD
Internal Address:	THIRD FLOOR
City:	BRIDGEWATER
State/Country:	NEW JERSEY
Postal Code:	08807

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	14603784

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: | lmurphy@dsiplaw.com Correspondent Name: | SERVILLA WHITNEY LLC Address Line 1: | 33 WOOD AVENUE SOUTH Address Line 2: | SECOND FLOOR, SUITE 210 Address Line 4: | ISELIN, NEW JERSEY 08830

ATTORNEY DOCKET NUMBER:	AMD0003-03CT
NAME OF SUBMITTER:	REBECCA A. SMIRK
SIGNATURE:	/Rebecca A. Smirk, Reg. #61295/
DATE SIGNED:	02/09/2015

Total Attachments: 11

source=00501565#page1.tif

source=00501565#page2.tif

source=00501565#page3.tif

source=00501565#page4.tif

source=00501565#page5.tif

PATENT REEL: 034915 FRAME: 0549

503170674



PATENT ASSIGNMENT

This PATENT ASSIGNMENT (this "Assignment"), dated as of / November, 2011, is made and entered into by and between Action Medicines, S.L., a company organized under the laws of Spain ("Assignor"), and AmDerma Pharmaceuticals, LLC, a Delaware limited liability company ("Assignee"). Unless otherwise defined herein, all capitalized terms used in this Assignment shall have the meanings set forth in that certain Purchase Agreement, dated as of November, 2011 (the "Purchase Agreement"), by and among Assignor, DermAct Pharmaceutical, Inc., a Delaware corporation ("DermAct") and Assignee.

WHEREAS, concurrently with the execution and delivery of this Assignment, Assignor, DermAct and Assignee are consummating the transactions contemplated by the Purchase Agreement.

NOW, THEREFORE, for good and valuable consideration as listed in detail in Section 4 of the Purchase Agreement, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

- Assignment. In accordance with and subject to the terms and conditions of the Purchase Agreement, Assignor does hereby acknowledge that it has sold, assigned, and transferred, and by these presents does hereby sell, assign, and transfer, unto Assignee, its successors, legal representatives, and assigns, Assignor's entire right, title, and interest throughout the world in, to, and under the patents and patent applications listed in Exhibit A attached hereto (the "Patents and Patent Applications"), including without limitation all patents and patent applications claiming priority to and/or benefit of the Patents and Patent Applications including but not limited to divisions, continuations, and continuations-in-part thereof and all reissues, reexaminations, and extensions thereof, and all priority rights under the International Convention for the Protection of Industrial Property for every member country, and all applications for patents (including without limitation related rights such as utility-model registrations, registrations, inventor's certificates, and the like) heretofore or hereafter filed in any country/countries foreign to the United States, and all patents (including all extensions, renewals and reissues thereof) granted for in any country/countries foreign to the United States. In addition, Assignor does hereby sell, assign, transfer and convey to Assignee, its successors, legal representatives, and assigns all claims for damages and all remedies arising out of any violation of the rights assigned hereby that may have accrued prior to the date of assignment to Assignee, or may accrue hereafter, including, but not limited to, the right to sue for, collect, and retain damages for past infringements of the said patents and patent applications before or after issuance. Assignor hereby authorizes and requests the United States Commissioner of Patents and Trademarks, and any officials of countries foreign to the United States whose duty is to issue patents on applications as aforesaid, to issue all Letters Patents resulting from the Patents and Patent Applications in the name of Assignee, its successors, legal representatives, and assigns, in accordance with the terms of this Assignment.
- 2. <u>Further Assurances</u>. AM further agrees that it will at any time and from time to time, at the request of AmDerma, execute and deliver to AmDerma all other and further instruments reasonably necessary to vest in AmDerma the right, title and interest in the Patent which this instrument purports to transfer to AmDerma.

- 2. <u>Limitation</u>. Notwithstanding anything to the contrary contained herein, the Assignee does not hereby assume or agree to perform or pay any liabilities or obligations of either Assignor that are not Assumed Liabilities.
- 3. <u>Amendments</u>. This Assignment may only be amended by a writing signed by each Assignor and Assignee.
- 4. <u>Counterparts</u>. This Assignment may be executed in counterparts, each of which shall be deemed an original and all of which shall constitute a single document.
- 5. <u>Delivery Pursuant to Purchase Agreement</u>. Notwithstanding anything to the contrary herein, Assignor and Assignee is executing and delivering this Assignment in accordance with and subject to all of the terms and provisions of the Purchase Agreement. To the extent of any conflict between the terms and conditions of this Assignment and the terms and conditions of the Purchase Agreement, the terms and conditions of the Purchase Agreement, the terms and conditions of the Purchase Agreement, supersede and prevail.
- 6. <u>Binding Effect.</u> This Assignment shall be binding upon, and shall inure to the benefit of, Assignors and Assignee and their respective successors and assigns.
- 7. Governing Law. This Assignment shall be governed by and construed in accordance with the laws of the State of New Jersey, without regard for conflicts of laws principles.

[SIGNATURE PAGE FOLLOWS]

PATENT

distribution of the first that the second IN WITNESS WHEREOF, this Assignment has been duly executed and delivered by the parties hereto as of the date first above written. draw for any war characteristic and complete and additional acceptance The error of the first of the second HMHM ASSIGNOR TO SEAL THE CORRESPONDENT the enterest of the control of a control of a stability of the control of emberger, altawater, his by earlier to be a ACTION MEDICINES, S.L. is made a firm or be do not the later and The street contribution in the state of Boston and An Name: Santiago de Gracia Title: CEO-Consejero Delegado Sign in presence of a Notary and have Notary attach Acknowledgement ASSIGNEE: AMDERMA PHARMACEUTICALS, LLC By: Title: Manager and Prosidet Sign in presence of a Notary and have Notary attach Acknowledgement Attorney at Law 1 State of NJ Avishu Pathak, ssq.

../... T I M A C I O N: -----

YO, MIGUEL KRAUEL ALONSO, Notario de Málaga, Ilustre Colegio de Andalucía . ------

VISTA Y LEGITIMADA: Doy fe que la firma y rúbrica que precede de DON SANTIAGO DE GRACIA CLEMENT con D.N.I./N.I.F. número 00100848-Q, la considero legitima por haber sido puesta a mi presencia y haberle identificado por su reseñado documento, que me exhibe y le devuelvo.-

En Málaga, a veintitrés de septiembre de dos mil once . APLICACION ARANCEL LEY DE TASAS HONORARIOS: 6,16 \in LIBRO INDICADOR: Hoja N° 260% Section 2°

E POTABILIS SO LE MALACIO

EXHIBIT A

TO

PATENT ASSIGNMENT

(See Attached)

PATENT

Ref		12.17	1771 : 11 TO 18 1	ing a second	Company of the state of the sta	\$ \$ \$ \d\$ \dag{\dag{\dag{\dag{\dag{\dag{\dag{	A17 - 211 1 1 1
No. ÷	Title of Invention	Country	Status	Appln No.	Filed	Patent No.	Issued
	ra solvadi bi solv	3634.5	was the in	wana i	8/2/2006	va i de valendo	Lister Lise
l i i	Use of Dihvoroxy-				PCTFHing		
10 h	benzenesultonic acids.	10 mg	Response to		Date		
	in the Production of Medicaments for		non-final GA		2/16/2005		
1 P 2	Angiogenic Diseases		filed 6/30/2010		Priority 2/16/2005	US20080293816	M) 19, 1
1770	such as Cancer and	H. Charles	awaiting to	in the state of the	(PCT Filing)	Pub date	
202()	Psortexis	US	PTO action	10/588,166	2/17/2004	11/27/2008	
-71 -91	Use of Diliyoroxy-	Step # 1			4,4 S	Lee Massay	9,50
M. T.	benzenesultonic acids						
	in the Production of	la i	Marija di kab	A STOTAL WY			
P2280 3BEE	Medicaments for		A.J.A.	rannadana.			
P	Angiogenesis- dependent Diseases	Belgium	Granted :	EP05708114	16/02/2005	EP1719509	
1 1	Use of Dihydroxy-	Destanti	vanuaisu	7 - Na - N	[· 16/02/2003 ·]	177664119909	
4 2 4 4 4 4	benzenesulionic acads			(A) (A)			
182	in the Production of				医产乳腺	[2] 《肾色》的形式	ng Sesilai
P2280	Medicaments for						
3DEE	Angiogenesis-	1.4	Granted	EP05708114	k ta a an		
P	dependent Diseases	Germany	Validated		16/02/2005	EP1719509	
1 40.6	Use of Dihydroxy-			外开放电流 设置			
1000	benzenesulfonic acids in the Production of			A galance ye			COLUMN.
P2280	Medicaments for	人名 墨沙瓦				E01719509	建工场影响
3DKE	Angiogenesis		Granted	EP05708114		DKIEP 1719509	
P	dependent Diseases	Denmark	Validated		16/02/2005		
4.5	Use of Dinydroxy	(1. pr.)	1 18 18 18 7 1 3	graph and gr		VERWING A PARK	
	benzenesulfonia acids	(Trive	ring figure a		1975 数数1		
P2280	mathe Production of	180					
3ES0	Medicaments for Angiogenesis	india in	医多类的结合	P200400371			
0	dependent Diseases	Spain	Granted	5	17/02/2004	FS2238C24AR	
7.773	Use of Dinverse						1977
19	benzenesülfonic acids				7、香罗香香		
	in the Production of					10月10年11月	[4] 计算数
P2280	Medicaments for	88.3.27 by			医氯磺基磺基		
3ESE	Angrogenesis denendent Diseases	Spain	Granted Validated	EP05708114	16/02/2005	EP17/9509 ES233444713	
4	Use of Dihydroxy-	жараш	· variantei		7110VU272003	1 Easjons 17 East	
	benzenesulfonic acids			14 - 14 (A)	l to day		
, A	in the Production of	医脱骨的		Contract Contract	TYPA NYA		
P2280	Medicaments for	1.			探视:	13 15 16 16 16 16 16 16 16 16 16 16 16 16 16	
3FRE	Angiogenesis		Granted	EP05708114	Kalaba	h Herring	
P	dependent Diseases	litance	. Validated	9 - 19 - 19 - 19 - 19 - 19 - 19 - 19 -	16/02/2005	EP1719509	11 1 1 2 1 1 N
	Use of Dihydroxy- benzenesulfonic acids	1 1 4 1 2 1 1 1		14.7 小五宝	医注 医蒙		· 道:: 在 / [3]
المرابا با	in the Production of	4.45			P. G. 1973	机工作的现代的	
P2280	Medicaments for	타일를 다	[] 《 [] []	$1.4 \pm k^{3}$			1.8
3GBE		United	Granted	EP03708114			
P	dependent Diseases	3 Kingdom	Validated	.3	16/02/2005	EP1719509	1.44
P2280	Use of Diliyoroxy-	Saul Fra			C. 130 60 75		
SIEE!		1 257	Granted 7	EP05708114		15	
P	in the Production of 📑	i. Ireland	Validated -	[##33 °. i	16/02/2005	部。2017年9509年美	15 15

A774132456

	Medicaments for Anguingenesis dependent Diseases					And the second	
P2280	Lise of Dihydroxy- bonzenesulfunic acids in the Production of Medicaments for Angioscocies		Granted	EP05708114		ERL719509	
P	dependent Diseases	Italy	Validated	8 x 10 + 10 2 1 3	16/02/2005	47515BE2010	196
P2280 3NEE P	Use of Dihydroxy- benzenesulfonic acids in the Profusion of Medicanomis for Anglogenesis- dependent Diseases	Netherlan es	.cimnted Validated	EP057081 [4	18/02/2005	EP1719509	
P2280 31/TE P	Use of Dithydroxy- benzenespillonic acids in the Production of Medicaments for Angiogenesis dependent Diseases	Portugal] Granted Validated	EP057081/4	16/02/2005	EP171 95 09	
P2803 SEEP	Use of Dilhydroxy- benzenesulfunic acids in the Production of Medicaments for Angrogenesis dependent Diseases	*Sweden	Granted Validated	EP05703114	16/02/2005	EP1719509	
PZ863 AUP C	Use of Dihydroxy- benrenesulfanic acids in the Production of Medicaments for Angrogenesis dependent Diseases	Ausralia		2005211956	16/02/2005		
P2803 CAP	Use of Diffydroxy- berganesul func scrids in the Production of Medicaments for Angiogenesis dependent Diseases	Canada		2:555:246	<i>16/02/2005</i>		
P2803 CNP	Use of Diliydroxy- benzenesiallonic scrids in the Production of Medicaments for Angregenesis dependent Diseases	China		2005800051 87.3	16/02/2003	CN:101014330A	
1280) [LPC	Use of Dihydroxy- benzenesulfonie acids in the Production of Medicaments for Anglogenesis- dependent Diseases	İsrael		17/7238	16/02/2005	A principle of the second of t	
#2803 EIPPC	Use of Dihydroxy- benzenesulfanje acida in the Production of Medicaments for			2006-1 553602	76/02/2005		

A774152456:1

i i	Angiogenesis- dependent Diseases	34.44 V				Tyrespa.	
4.	Use of Dinydroxy- benzenesulfonic acids						
P2803	in the Production of Medicaments for	richten. Mannet					
MXP C	Angiogenesis dependent Discuses	Межко	Corented	PAIA120061 009295	16/02/2005	269609	
ARC ARC	Use of Dinydroxy- benzenesulfonic acids						
P2803	in the Production of Medicantents for						
UAP	Angiogenesis dependent Diseases	Ukraine	Granted	2006 09127FM	16/02/2005	36399	
1.3					8/16/2006 CIP of		
1 14 1					10/588,166 above filed		
1.74	Methods of use for		Response to final Office		8/2/2006 (Nati Phase		
17.68	2,5-dihydroxybenzene sulfonic acid		Action and RCE filed.		Filmg) 2/16/2005		
2000	compounds for the Treatment of Cancer,		12/28/2009 > awaiting PTO	yazenz azn	(PCT Files)	LIS20070149618	
202.2	Rosacca and Psoriasis	TitUS A	acion	11/506:469	2/17/2004 8/15/2007 8/16/2006	Pub.date 6/28/2007	
					and CIP of 11/506.469a		
1 6 6					bove filed 8/16/2006		
(g)			Notice of		which is CIP		
25 A			Appeal filed 4/15/2010		10/588,166 above filed		
			Response to final OA med		8/2/2006/Na 1 Phase		
	Lise of Dihydroxy-		RCE 80e 10/15/2010		Filing) 2/16/2005		
1 % C %	derivatives for Treating Actinic		(6/1) FINAL desdine		(PCT Eding)	US20080123485	
202	Keratosis	i vos	41/15/2010 7/7)	1,1/839,508	2/17/2004 Divisional	Pub date: 5/29/2008	TENTE NORTH
1 000					of 11/506.469.		
2 1 1					above filed 18/16/2006;		
Angel and Angel					wbin is a CIP of	1- 新文 标识 [] [] [] []	
	Methods of use for 2,5-dihydroxybenzeric				10/588.166, above filed		
	suttonic acid Conrecunds for the		Pending		18/2/2006(Na 1. Phase		1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1
202-3	Treatment of Cancer, Rosacca and Psoriesis	lus -	awaiting PTO	12/257.854	Filing (2)16/2003	US20090111779 Pub.date 4/30/2009	1984 A ST

KJ74182456;1

4			
. 8)			PCT Piling
			3 2/17/2004
	Use of Dirtydroxy-		
1743	henzenesulionie		网络名词形形名 医肾髓炎 医二氏性 医二氏性 医二氏性 医二氏性 医二氏性 医二氏性 医二氏性 医二氏性
ma tura	derivatives for	The state of the s	
P3195 EPPC	Ereating Actinic Keratosis BU		142 2012/2007 UZDO 052/051

A/74152456.1

1		1 7 7 7	. जि. एक स्टूटिंग	er if (2)	FO	Figure Security in 1978	real provide
Ref No.	Title of Invention	Country	Shatus	Appln No.	Filed	Patent No.	lasued
		70 (* 13)	Final CA	VEN 19		N. P. P. P. A. R.	
			7/1/2010	lle ava			有数据 [187]
			Response to				
	Use of Dihydroxy		final OA 10//2010		第二种 原	小小腿 毛皮	
1 500	benzenesulfonic		(1/6) Final			经现实的证据	Dustrick Samuelan
10:1	derivatives for		dendline			US20080114075	
203	Treating Dermatitis	US	1/1/2011 (6/6)	(1/839,5) 2	8/16/2006 7/2/2007	Pub.detc 5/15/2008	
C Lake	Use of Dihydroxy-		THE LINE THE		INCOLUMN Value at the		ige of the second of the seco
P319	benzenesulionic derivatives for	1.70	N. S. Land				
6EP	Treating			EP077884			
PC -	Dematriis	EU .	Final OA	26.0	8/15/2007	EP2056815	
		300	mailed				
19 1			5/5/2010				
			Response to tand				
10.00	Use of 2.5-		RCE				
	dibydroxybenzene	,	10/5/2010		AND THE P		
1.45	compounds and Derivatives for the	111 12 . 146 150 - 255	(5/6) Front deadline		8/16/2006	US20080113947	
74.15	Treatment of		11/5/2010	11/839,51%		Politicate *	
204	Rosacea Use of Dihydroxy	US)16/6)	5.7 (1.7 5)		5/15/2008	· 1 法 家 。
	benzenesui ionic					行るのでは1年の10年代 10日 - 14年の17日の17日	
P319	derivatives for the	l in A. A.		****	A CONTRACTOR		
BED .	Treatment of Rosacea	eu /		EP077884 28.6	8/15/2007	EP2056813	级速液
1 1 1 1 1 1 1 1	Promote the state of the state	14 3 V	Final OA	\$ 35 kg	1		14 P. 140
1.5	N 7009-52-1		mailed 5/21/2010			物多数 "大	
1		Paris	Response to				
100	Uso 6125- 1		final OA and RCE	in the	1 4	[建] [] [] [] []	7 / eyolor 2013/03/49
	dihydroxybenzene		RCE 10/21/2010	10.20元			
	compounds and	物系统	(5/6) Final	墨灣藍			TO THE STATE OF TH
	Derivatives for the Treatment of		d56dline -11/21/2010	/1/810-52	8/16/2006	US20080113948 Pub date	
205	Psoriasis	บร	(6/6)	¥2:0 ·	7/2/2007	3/15/2008	The street
	Use of Dihydroxy- benzenesülfonic /		The San Joshi	Å) r			
P319	derivatives for the				医科器		
9EP	Treatment of	H. N	SPANIS A	EP077884		n andre	Witt.
PC :	Psoriasis Use of 2.5-	ÆÜ		29.4	8/15/2007.3	EP2056814	
	dinydroxybenzene		Response				
	Derivatives for the		filed 7/26/2010	1,0		US20080174060	
$\mathbb{E}^{(\frac{1}{2}, \mathbb{Z}_{k}, \mathbb{Z}_{k})}$	Treatment of Skin.		awaiting PTO.	11/839.52	8/16/2006	Pub date	k i kai
206	Cancer	the cos 🟥	action	.22.>r ≱	7/2/2007	5/15/2008	

A/74152#56:1

Skin Penetration Entercing 210. Systems for Polar	(Na Stage	sking storal Engrid 12/467,87	Fring-date 2/17/2009 Priority 2/15/2008 (US Trovisions 3)	
Processes for the Preparation of 2.5 till yellow a contract of the Preparation of 2.5 till yellow a contract of the contract o	Pe Na Singe	/2010) 5 andring itional Entered 12/811/62 /2010) 1	Priority 1/3/2008 Filling date 1/2/2009	NA NA

A/74152456;

PATENT

REEL: 034915 FRAME: 0561

RECORDED: 02/09/2015